Thus, in the type 1 diabetic patient when an SGLT2 inhibitor is utilized the dose of preprandial short-acting insulin can and should be reduced and on occasion can even be omitted which will reduce the risk of hypoglycemia. The gene discussed is SLC5A2; the disease is Hypoglycemia.